“Together, these in vitro studies suggest that Paxlovid is able to maintain a plasma concentration many times greater than that required to prevent omicron replication in cells,” the company said in a statement.

Earlier, the US medical regulator FDA approved Pfizer's coronavirus pill for emergency use.